MSDC 0602
CAS No. 1133819-87-0
MSDC 0602( MSDC-0602 | MSDC0602 )
Catalog No. M19353 CAS No. 1133819-87-0
MSDC-0602 is an insulin sensitizer potentially for the treatment of diabetes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 55 | In Stock |
|
| 2MG | 32 | In Stock |
|
| 5MG | 49 | In Stock |
|
| 10MG | 72 | In Stock |
|
| 25MG | 141 | In Stock |
|
| 50MG | 230 | In Stock |
|
| 100MG | 368 | In Stock |
|
| 200MG | 538 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMSDC 0602
-
NoteResearch use only, not for human use.
-
Brief DescriptionMSDC-0602 is an insulin sensitizer potentially for the treatment of diabetes.
-
DescriptionMSDC-0602 is an insulin sensitizer potentially for the treatment of diabetes (metabolic modulator).
-
In Vitro——
-
In VivoAnimal Model:HTF-C diet feeding C57BL6/J mice Dosage:331 ppm MSDC-0602 potassium salt (2-5 μM MSDC-0602 in blood)Administration:oral administration for 12 weeks (after 4 weeks of HTF-C diet) or 3 weeks (16 weeks after HTF-C diet)Result:Induced weight loss, decreased concentrations of plasma ALT and AST and stellate cell activation.Animal Model:HTF-C diet feeding LS-Mpc2-/-C57BL6/J mice Dosage:331 ppm MSDC-0602 potassium salt (2-5 μM MSDC-0602 in blood) Administration:oral administration for 12 weeks (after 4 weeks of HTF-C diet)Result:Induced weight loss, suppressed stellate cell activation.
-
SynonymsMSDC-0602 | MSDC0602
-
PathwayOthers
-
TargetOther Targets
-
RecptormTOR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1133819-87-0
-
Formula Weight371.4
-
Molecular FormulaC19H17NO5S
-
Purity>98% (HPLC)
-
SolubilityDMSO : 125 mg/mL 336.56 mM; H2O : < 0.1 mg/mL
-
SMILESCOc1cccc(c1)C(=O)COc3ccc(CC2SC(=O)NC2=O)cc3
-
Chemical Name5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.McCommis KS et al. Hepatology. 2016 Dec 27. doi: 10.1002/hep.29025.
molnova catalog
related products
-
Nodakenetin
Nodakenetin has clinical efficacy.
-
neo-gambogic acid
Neogambogic acid an active ingredient in garcinia can inhibit the growth of some solid tumors and result in an anticancer effect it may be responsible for the inhibition of proliferation of human breast cancer cell line MCF-7 cells.
-
1-Hydroxybaccatin I
1-Hydroxybaccatin I possesses significant antinociceptive activity against p- benzoquinone-induced abdominal contractions.
Cart
sales@molnova.com